Annual report pursuant to Section 13 and 15(d)

License, Collaborative and Employment Agreements and Commitments (Details Textual)

v3.10.0.1
License, Collaborative and Employment Agreements and Commitments (Details Textual) - USD ($)
1 Months Ended 12 Months Ended
Sep. 05, 2018
Dec. 04, 2017
Dec. 04, 2015
Aug. 10, 2015
Dec. 05, 2013
Oct. 05, 2012
Dec. 06, 2018
Nov. 30, 2017
Jan. 17, 2017
Nov. 30, 2016
Aug. 31, 2015
Aug. 29, 2015
Apr. 28, 2015
Dec. 19, 2012
Nov. 28, 2012
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2012
Oct. 15, 2018
License, Collaborative and Employment Agreements and Commitments [Line Items]                                          
Line of Credit Facility, Periodic Payment, Interest                               $ 381,150          
Research and Development Expense $ 102,000                             11,844,000 $ 18,784,000        
Operating Leases, Rent Expense                               201,000 199,000        
Salary and Wage, Officer, Excluding Cost of Good and Service Sold                                     $ 385,000    
Operating Leases, Future Minimum Payments Due, Next Twelve Months                               $ 300,000          
Payments for Other Fees               $ 4,500,000                          
Payments to Acquire in Process Research and Development 321,000                                 $ 643,000 $ 424,000    
Exchange percentage of unregistered common stock                               50.00%          
Proceeds from (Repurchase of) Equity                               $ 3,000,000 $ 3,000,000        
Options To Be Received Common Stock Shares                               2,000,000          
Shares Issued, Price Per Share                                         $ 1.15
Fair Value Of Shares Issued $ 285,000                                        
Synthetic Biomics Inc [Member]                                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                                          
Additional Number Of Common Stock To Be Issued 2,420,000                                        
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners (17.00%)                                        
Stock Purchase Agreement [Member]                                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                                          
Research and Development Expense $ 36,000,000                                        
Conversion of Stock, Shares Converted                       38,572                  
Conversion of Stock, Shares Issued                     38,572 38,572                  
Channel Collaboration Agreement [Member]                                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                                          
Shares, Issued       26,786                                  
Stock Issued       $ 3,000,000                                  
Licensing Agreements [Member]                                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                                          
Payments for Other Fees         $ 150,000                                
Stock Issued During Period, Shares, New Issues         9,569                                
Patents [Member]                                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                                          
Payments for Other Fees         $ 220,000                                
Riley Employment Agreement [Member]                                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                                          
Salary and Wage, Officer, Excluding Cost of Good and Service Sold   $ 200,000                                      
Deferred Compensation Arrangement with Individual, Compensation Expense     $ 550,000           $ 385,000             $ 5,397          
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage     75.00%           75.00%                        
Shallcross Employment Agreement [Member]                                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                                          
Cash Payment for License Agreement                               (8,000)          
Deferred Compensation Arrangement with Individual, Compensation Expense             $ 550,000           $ 315,000                
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage             75.00%           75.00%                
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross                         25,714                
Jeffrey Riley [Member]                                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                                          
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage                                     75.00%    
Steven A. Shallcross [Member]                                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                                          
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value                                     $ 1,900,000    
Deferred Compensation Arrangement with Individual, Compensation Expense                   $ 346,500                      
Intrexon [Member]                                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                                          
Research and Development Expense                                       $ 7,800,000  
Stock Issued During Period, Shares, Acquisitions           101,492                              
Shares Issued, Price Per Share           $ 0.001                              
Milestone Payment upon First Dosing       $ 2,000,000                       2,000,000          
Prev Abr Llc [Member]                                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                                          
Additional Cash Payment for License Agreement                             $ 235,000            
Unregistered Shares Issued to License Agreement                             17,858            
Additional Consideration Payable                             50% in cash and 50% in our stock            
Options To Be Received Common Stock Shares                                     18,724    
Cedars-Sinai Medical Center [Member]                                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                                          
Number Of Common Stock To Be Issued (50,000)                                        
Cedars-Sinai Medical Center [Member] | Synthetic Biomics Inc [Member]                                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                                          
Additional Number Of Common Stock To Be Issued (2,420,000)                                        
Number Of Common Stock To Be Held By Related Party (7,480,000)                                        
December 31, 2014 [Member]                                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                                          
Operating Leases, Future Minimum Payments Due, Next Twelve Months                           $ 50,000              
December 31, 2015 [Member]                                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                                          
Operating Leases, Future Minimum Payments Due, Next Twelve Months                           25,000              
Phase I Clinical Trials [Member]                                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                                          
Milestone Payment                           50,000              
Phase III Clinical Trials [Member]                                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                                          
Milestone Payment                           100,000              
NDA Submission In US [Member]                                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                                          
Milestone Payment                           250,000   $ 2,500,000          
European Medicines Agency Approval [Member]                                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                                          
Milestone Payment                           100,000              
Regulatory Approval In Asian Country [Member]                                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                                          
Milestone Payment                           100,000              
First Year [Member]                                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                                          
Research Agreement Fixed Fee                           303,287              
Second Year [Member]                                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                                          
Research Agreement Fixed Fee                           316,438              
Third Year [Member]                                          
License, Collaborative and Employment Agreements and Commitments [Line Items]                                          
Research Agreement Fixed Fee                           $ 328,758